Factors influencing survival in patients with multidrugresistant Acinetobacter baumannii infection

Brazilian Journal of Infectious Diseases

Volumn 16, Issue 3, 2012, Pages 237-241

  Prata Rocha, Mariana Lima ^a   Gontijo Filho, Paulo Pinto ^a   de Melo, Geraldo Batista ^a  

^a FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

Author keywords

Acinetobacter baumannii; Gram negative bacteria; Multidrug resistant

Indexed keywords

ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ADULT; AGE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM ISOLATION; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; INVASIVE PROCEDURE; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PARENTERAL NUTRITION; PNEUMONIA; PROSPECTIVE STUDY; SURGERY; SURVIVAL PREDICTION; TERTIARY HEALTH CARE; TREATMENT OUTCOME;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAZIL; CHILD; CHILD, PRESCHOOL; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84862005193     PISSN: 14138670     EISSN: 16784391     Source Type: Journal    
DOI: 10.1016/S1413-8670(12)70317-3     Document Type: Article

References (11)

1. Garcia-Garmendia J.L., Ortiz-Leyba C., Garnacho-Montero J., Jiménez-Jiménez F.J., Monterrubio-Villar J., Gili-Miner M. Mortality and the increase in length of stay attributable to the acquision of Acinetobacter in critically ill patients. Crit. Care Med. 1999, 27(9):1794-1799.
2. Lee K., Lim Y.S., Yong D., Yum J.H., Chong Y. Evaluation of the Hodge test and the imipenem-EDTA double disk synergy test for differentiating metallo-beta-lactamase-producing isolates of Pseudomonas spp and Acinetobacter spp. J. Clin. Microbiol. 2003, 41:4623-4629.
3. Performance standards for antimicrobial susceptibility testing: eighteenth informational supplement 2008, Clinical and Laboratory Standards Institute, CLSI, Wayne, PA, Document M100-S18.
4. Maragakis L.I., Perl T.M. Acinetobacter baumannii: epidemiology, antimicrobial resistance and treatment options. Clin. Infect Dis. 2008, 46(8):1254-1263.
5. Baran G., Erbay A., Bodur H., et al. Risk factors for nosocomial imipenem resistant Acinetobacter baumannii infections. Int J Infect Dis 2008, 12(1):16-21.
6. Grupper M., Sprecher H., Mashiach T., Finkelstein R. Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Cont Hosp Epidemiol 2007, 28(3):293-298.
7. Koprnová J., Svetlanký I., Babel'a R., et al. Prospective study of antibacterial susceptibility, risk factors and outcome of 157 episodes of Acinetobacter baumannii bacteremia in 1999 in Slovakia. Scand J Infect Dis 2001, 33(12):891-895.
8. Kwon K.T., Oh W.S., Song J.H., et al. Impact of imipenem resistance on mortality in patients with Acinetobacter bacteremia. J Antimicrob Chemother 2007, 59(3):525-530.
9. Falagas M.E., Kasiakou S.K., Rafailidis P.I., Zouglakis G., Morfou P. Comparison of mortality of patients with Acinetobacter baumannii bacteremia receiving appropriate and inappropriate empirical therapy. J Antimicrob Chemother 2006, 57(6):1251-1254.
10. Gordon N.C., Wareham D.W. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Inter J of Antimicrobial Agents 2010, 35:219-226.
11. Hernández-Torres A., García-Vásquez E., Gómez J., et al. Colonización; infección por Acinetobacter bamannii multirresistente y resistente a carbapenêmicos: epidemiologia y factores predictivos de infección. Méd Clin 2010, 135(9):389-396.